Hepatitis
Show Only Open Trials
1.
Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy
- Study Status: Open to Enrollment
- Sponsor: Bristol-Myers Squibb
- Disease Status and/or Stage: Chronic Hepatitis C, Untreated or Previously Treated
- Protocol ID: BMS AI452021
2.
GS-US-321-0105: GS-6624 in the Treatment of Liver Fibrosis in Subjects With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)
- Study Status: Open to Enrollment
- Sponsor: Gilead
- Disease Status and/or Stage: Advanced Liver Fibrosis as a Result of NASH (non-lcoholic steatohepatitis)
3.
GS-US-321-0102: GS-6624 in the Prevention of Progression of Liver Fibrosis in Subjects With With Primary Sclerosing Cholangitis (PSC)
- Study Status: Open to Enrollment
- Sponsor: Gilead
- Disease Status and/or Stage: Primary Sclerosing Cholangtis (PSC)
- Protocol ID: GS-US-321-0102
4.
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection (GS-US-283-0102)
- Study Status: Closed to Enrollment
- Sponsor: Gilead
- Disease Status and/or Stage: Chronic Hepatitis B
- Protocol ID: GS-US-283-0102
5.
Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination With Peginterferon α-2a vs Standard of Care Tenofovir Disoproxil Fumarate Monotherapy or Peginterferon α-2a Monotherapy for 48 Weeks in Chronic Hepatitis B
- Study Status: Closed to Enrollment
- Sponsor: Gilead Sciences, Inc.
- Disease Status and/or Stage: Chronic Hepatitis B
6.
A5294: A Prospective, Phase III, Open-Label Study of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in HCV/HIV Coinfected Subjects
- Study Status: Open to Enrollment
- Sponsor: NIAID
- Disease Status and/or Stage: HIV/Hepatitis C Co-Infection
7.
A long-term monitoring study to evaluate the persistence of direct acting antiviral (DAA) treatment-resistant mutations or the durability of sustained virological response in patients treated with DAA-containing regimens for chronic hepatitis C infection
- Study Status: Open to Enrollment
- Sponsor: Roche
- Disease Status and/or Stage: Chronic Hepatitis C
